Advanced

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Norlin, Jenny M.; Steen Carlsson, Katarina LU ; Persson, Ulf LU and Schmitt-Egenolf, Marcus (2012) In Dermatology 225(4). p.326-332
Abstract
Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Outcomes of biological-naive patients who switched to a biological agent (n = 267) were... (More)
Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Outcomes of biological-naive patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI >= 10 and/or PASI >= 10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores. Copyright (c) 2013 S. Karger AG, Basel (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biological agents, Psoriasis, EQ-5D, DLQI, PASI, Register
in
Dermatology
volume
225
issue
4
pages
326 - 332
publisher
Karger
external identifiers
  • wos:000315976300007
  • scopus:84875216586
ISSN
1421-9832
DOI
10.1159/000345715
language
English
LU publication?
yes
id
8e63c41e-ff9d-4bf8-84eb-4b2033d1da9e (old id 3674847)
date added to LUP
2013-05-02 08:51:49
date last changed
2017-10-22 03:31:10
@article{8e63c41e-ff9d-4bf8-84eb-4b2033d1da9e,
  abstract     = {Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Outcomes of biological-naive patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p &lt; 0.001). Patients with DLQI &gt;= 10 and/or PASI &gt;= 10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores. Copyright (c) 2013 S. Karger AG, Basel},
  author       = {Norlin, Jenny M. and Steen Carlsson, Katarina and Persson, Ulf and Schmitt-Egenolf, Marcus},
  issn         = {1421-9832},
  keyword      = {Biological agents,Psoriasis,EQ-5D,DLQI,PASI,Register},
  language     = {eng},
  number       = {4},
  pages        = {326--332},
  publisher    = {Karger},
  series       = {Dermatology},
  title        = {Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice},
  url          = {http://dx.doi.org/10.1159/000345715},
  volume       = {225},
  year         = {2012},
}